The journalistic stereotypes -of BGI, the world's largest sequencing center, as a Chinese state venture, and of Singapore's GIS as a neoliberal platform -are inverted.
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The way that we look at them is very clear: their pedigree, their accomplishment, their energy, and how forward looking they are.
GIS senior administrator on selecting GIS Fellows, April 2015 Introduction
In a previous essay (Fischer, 2013a) , I described the unfolding of the first ten years of the Genome Institute of Singapore (GIS), as part of the large Biopolis life sciences enterprise in Singapore, itself part of a series of larger research and development and educational initiatives, directed both at positioning in a global landscape and at creating a new Singaporean grown and staffed knowledge economy. That essay ended with an effort by A*STAR (Agency for Science, Technology and Research), the funding agency, to redirect the institutes from only basic science to more alignment with both industry ('biologics', patents) and clinical science ('translation'). In the present essay, I want to briefly explore how that reorganization has played out amidst a series of subsequent shifts. However, I don't want to just focus on the Singapore story, but attempt to begin a larger comparative discussion of charismatic and institutional growth with a focus on what I will call qualitative networks, by juxtaposing the case of another well-known genome institute, BGI in Shenzhen, China. i I will do so in a slightly different manner than the comparative component in the first essay on the scientific contributions to the stemming of the SARS pandemic and the building of transnational infectious disease monitoring and biosecurity systems at GIS and in Hong Kong.
Traditionalists may balk at the strategy of juxtaposition rather than direct comparison, but I argue that in the complex world of the life sciences, it can be more productive to engage a set of mixed methods in order to begin to characterize the institutional fields of emergence and competition. I have called earlier ethnographic forms of this approach a "mosaic approach," "an ethnographic jeweler's eyed detailing of emergent "third spaces", "multi-locale approaches" (or now more widely called "multi-sited" approaches," and attention to the "peopling of technologies." ii These are tools both for globally distributed, multi-scalar, and locally differently grounded processes, such as the growth of the chemical and nuclear industries and their trailing toxic clean-up imperatives (Fortun, 2001; Petryna, 2001) , the pharmaceutical industries and their trailing health care system imperatives (Biehl and Petryna, 2013; Petryna, 2009; Sunder Rajan, 2006 Waldby and Cooper 2014) , global oncology clinical trial platforms and protocols (Keating and Cambrosio, 2012) , climate change science and local vernaculars of appropriation and resistance (Callison 2014) , and, here, more generally, the basic life sciences and their translational imperatives. Juxtaposition is a tactic of not abstracting from context (the bane of moving too quickly to generalization and comparative evaluation), while yet being able to gain a perspective on similarities and differences that may open up new ways of doing things in the varied local sites (Marcus and Fischer, 1999) .
While I have longer fieldwork experience in Singapore, I have talked to the three founders of BGI, listened to them on several occasions, particularly at five annual meetings of the Human Genome Organization. Again, this is not a comparison of the two Genome Institutes, but rather I want to look more closely at one telling by one of the three founders of BGI, to highlight the role of cross-national networks in the construction of what are usually seen as national science projects.
As one listener to the original presentation of this essay (and fellow STS scholar of Asian science) warned, Wang Jian's version of the story is not the only one, and yet she agreed, as long as it is marked as his account, it is an important and valid one.
And, for my purposes in this essay, it raises for me a series of structural insights and questions, access for further exploration into the global competitive dynamics of the life sciences. iii Methodologically, in one sense, it draws upon the experiments to reinvent or refunction the ethnographic interview that were explored in the 1990s in the eight volumes of the Late Editions Project, edited and guided by George E.
Marcus, and published by the University of Chicago Press (Marcus, ed., 1993 (Marcus, ed., -2000 .
At issue in those experiments was an informed encounter, ethnographic contributions, rather than merely interviews, having to do in part with strategic access points in processes that are not visible or available in conventional accounts 4 (see those volumes and especially their methodological introductions and conclusions for further elaboration).
In the present case, I am interested in both what I call in the title "qualitative networks," that is, mentorship and friendship relations that are part of the small worlds of the scientific republic (a transnational mapping that acknowledges but transcends and often contests political boundaries and national projects), and in what I call the charismatic voice. I've dealt with the charismatic voice in various ways before, as an interest in the "lively languages" that scientists use (and that often provide metaphors for changes in lay consciousness, as well being a two way street between science and popular culture), the "songs and under-songs," of science (that is the debates about ethics, ability to foretell abuse and misuse of new developments, or more generally fears and grounds for reassurance), and particularly with capturing the tonalities, nuances, and resonances that scientific leaders use when they are in their most lucid and explanatory moments. I have tried to capture that lucidity and expressiveness explicitly with Dr. Judah Folkman's account of the angiogensis inhibitor story for cancer therapy (Fischer, 2010 (Fischer, , 2012 , and in a slightly different way with discussions of scientists' autobiographical accounts, as opposed to biographical accounts (1994, 1995, 2003, 2009 ).
I am less concerned in this piece with variants of founding stories than with drawing attention to forms of network analysis that include mentorships, funding, and political leverage that can help institutions against internal inertial and bureaucratic blockages. One might call this rhyzomic networks if one wants a fancy word, but "qualitative" may be simpler and just as good. In part I of this essay, I
will, very briefly, bring the account of the Genome Institute of Singapore up to date as it prepares for yet another five year plan for funding. In part II, I present an account of BGI in Shenzhen that may complicate stories that contrast the GIS as driven by transnational "foreign talent" in an effort to create a new Singaporean scientific community, and that see BGI as a state enterprise that can use state backing to underprice services to gain market advantage (e.g. Lauerman, 2012) . As Wang Jian points out, much of the stereotyped discourse generated in competitive publicity is not only unfair, but also a source of misrecognition. My first fieldwork report on Biopolis and GIS chronicled the three areas of scientific advance that put the Genome Institute of Singapore (and its sister biology institutes) on the global map as a scientifically competitive basic science research center: first, infectious diseases with the role of GIS in the SARS crisis; second, "scientific diplomacy" in moving the office of the Human Genome Organization to GIS and using a molecular anthropology research project to begin establishing working relationships between richer and poorer scientific communities in the PanAsian region, the Pan-Asian SNPs Consortium; and third, the productivity of papers in the realm of iPS stem cell research, cancer, and tissue repair.
That paper (Fischer 2013a ) ended chronologically with the aftermaths, short-term anxiety, and shifts, that followed the October 2010 decision to 'industrially align' the seven basic biology research institutes of Biopolis. This decision came suddenly, like a Friday decision in the business world (viz. Judah Folkman in Fischer, 2010 Fischer, , 2012 . Not only did the charismatic founding director of the Genome Institute leave Singapore for a parallel effort in the U.S., followed by several key P.I.s (principal investigators), but there ensued two years of anxiety and downsizing as budgets were withheld and mortgaged. More P.I.s were let go because their direction of research no longer fit with the projected directions of the Institute. A couple of younger scientists were promoted to senior P.I. status. Two intense years followed of writing many grant applications, of working out contracts with the commercial biotechnology and pharmaceutical worlds, and working out collaborations with the clinician community (especially in eye diseases, and lung cancer research).
More generally, it was a time when there seemed to be a more general move in national and transnational research agendas towards the cell as increasingly available as a unit of study, rather than the twentieth century focus on the gene, and thus towards epigenomics, developmental biology, cell reprogramming; and commercially towards biologics or cell based production of medications rather than chemical pharmacology.
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GIS emerged by the turn of 2015 with a new set of networks, pipelines, and collaborations --with clinicians in cancer research at several hospitals, research and licensing collaborations with biotech companies such Fluidigm and Singapore based SG Microlab Devices and with a couple of hopeful start-ups. Today preparations are under way for a new five year cycle of funding, 2015-2020, and with a number of new players in the game in Singapore. Not only has money been shifting to the now world-ranked research universities, scholarships for non-Singaporeans are being reduced, and Merck has come to try to engage more fully with the Singapore research community by hiring a member of GIS as its point person for identifying scientists and projects with whom it might collaborate, attempting to bring together the resources and ways of moving projects through the pipeline of big pharma with the cutting edge insights in more nimble upstream research groups.
GIS sees itself now as a mature and stable Institute, with a process of continual renewal, having promotional positions parallel to university ranks of assistant professor (senior research scientist), associate professor (group leader) and full professor (senior group leader) as well as Fellows (returnees from A*STAR's ambitious program of scholarships for training at the BSc, PhD, and postdoc level in leading universities and laboratories abroad). As new investigators are hired at all levels, the focus of the Institute shifts with their interests, grants, and strategies.
Transition Period 2011 -2015 'Friday decisions' happen more often in business than in academia or national research labs, and are often assessed in terms of pure returns on investment, efficiency and flexibility in conducting mergers and alliances, and in reasonably informed bets on near and medium term research and development market deliverables (Fischer, 2012 (Fischer, , 2010 . A Singapore sport is to count which pharmaceutial multinationals withdraw or invest locally, and in what they invest.
There was a stir when Eli Lily withdrew from Biopolis in 2010 seemingly to be replaced by a major investment by Proctor and Gamble, seen by cynics as a move This is already the case in countries such as Japan and Singapore. There will be something like 150 million cases of Alzheimers, something that could be unsustainable for public health care systems as well as families, especially given the care-giver burdens.
The pharmaceutical industry, however, was shutting down its neuroscience research and exiting psychiatry. A few Alzheimer's drug trials were in process, but if they failed, their pharmaceutical sponsors would also exit. A key reason is that drug discovery in this arena has been unsuccessful. The pharmaceutical industry has made large profits off of new drugs that have provided some increased tolerability and safety, but no fundamentally new mechanisms of molecular action.
Ironically most of the drugs we still use were discovered in the 1950s by accident, were tested immediately on humans in ways that would be unthinkable under IRB Paper on the potential ethical issues that may emerge with developments in neuroscience (Fischer 2013b; BAC, 2013) , and one of its members, the Chair of Ethics at the NUS Medical School, advised the Necessary Theater on a play that addressed questions of genetic engineering.
Neural stem cells are among the hot topics in stem cell biology; we are still at the stage of learning through induced pluripotent stem cells, made from adult skin and other cells, how to make neural cells, stablize them, and integrate them with other cells into functional therapies. The hope is to be able to inject, engraft, or engineer them to correct an identified genetic defect. Stem cell therapy clinical trials for disabled stroke victims began in November 2010 in Scotland. But this is fraught territory as yet: one needs to watch for tumor development, inappropriate stem cell migration, virus infection, and immune rejection. These are not reasons to stop, but on the contrary the biology challenge is to learn how and why these things might occur and how to short circuit, avoid, or counter them, or how to proceed otherwise. In the meantime, GIS continues to work in the fast moving field of blood stem cells and lung repair stem cells.
Looking Ahead 2015-2020
GIS is something like a bonsai, says the director: you plant and shape it, and let it grow in all directions, and then begin to reshape it. An important direction is the growing importance of computation in molecular biology, and in the past three and a half years, the number of principal investigators on the computational side of the Institute has grown from four to nine (out of a total of 26 principal investigators). A longer term goal is gradually finding cross-trained individuals who bring dual skill sets of the wet lab and computation. Already, of course, the computational folks are deeply informed in the biology: one cannot just hire a computer scientist and ask for help in analyzing biological data (we are long past that era). While people with such double skill sets are still rare, GIS's young recruits Daley's and Lewis Cantley's labs at Harvard, and one from Robert Weinberg's lab at MIT Whitehead Institute.) The first already produced, while at Stanford, a Nature paper as first author and co-corresponding author, and is developing a high through-put approach to understand the structure of RNA, which unlike DNA (a linear double helix structure), folds into domains and requires new techniques to probe. She promises to become a leader in this field, and already has won a prestigious Branco Weiss Fellowship grant. She does wet lab work, and thus needs to work closely with computational people, a capacity in which GIS has now been building strength. The second comes with six papers on which he is first author and a corresponding author (plus six other papers). He works on muscle stem cell metabolism during regeneration and aging. The ability to modulate metabolic networks to regulate stem cell proliferation and differentiation is directed towards Today BGI is beginning its own Academy for training its personnel which eventually will be a degree-granting institution. The average age of BGI's four thousand employees is 26, and for the scientific group it is under 24, "so it is lots of young kids" (Wang Jun, MF interview April 2013) . This is admittedly a transition with its own challenges, as is the effort to set up not just service organizations across the globe, but more importantly data collecting operations across China that can be trusted to produce quality back when we said that we need 20,000 samples, then 45,000. Today less than 10% we understand from the type 2 diabetes from the DNA sample. Now you are saying let's go and do 100,000 or more samples. Do you think this approach is the only solution or we have to sit back and now ask at the last slide of yours saying it is so complex, let's go back and do hypothesis-driven discovery, rather than dataintensive discovery. Data intensive discovery means data will speak, it'll converge, it will come out of its own pattern, and from the pattern we should be able to interpret. It looks to me variation is multi-layer, At issue in this exchange is the strategy of stratified medicine or better targeting of why drugs work for some patients and not others, leading it is hoped eventually to personalized medicine, therapies that take into account an individual's particular make up: his or her genetics as well as habits, diets, and travels through microbiotic fields. The example Wang Jun used in his talk on BGI's current research and its "dream-line" strategies for the future was Type 2 Diabetes (T2B) in China. He went on to say that we still talk of T2B as if it were one phenotype, but now with the ability to look at not just genomics, but proteomics, metabolomics, and, especially, now gut bacterial communities, we should be able to stratify T2D into thousands of types so that one can then go back and look at the genetics and get more significant statistics that can target different therapies for different groups or individuals. This is no minor matter: thirty years ago, the prevalence of T2D in China was less than 1%, 0.6-7% of the adult population; in 2012 it was over 10% and pre-diabetics were another 15%. So a quarter of the adult Chinese population is either diabetic or prediabetic. (This gathering storm, of enormous concern for health care budgets, interestingly is almost identical in numbers and distribution to the gathering storm of chronic obstructive pulmonary disease [Rebuck et al., 2013] ).
Studies being conducted by BGI, Copenhagen University, and Novo Nordisk
Foundation Center for Basic Metabolic Research, and in association with the MetaHIT Consortium in Europe have begun identifying biomarkers in the bacterial colonies of the gut for diabetes and other diseases. At issue is the ability to correlate or triangulate a series of different kinds of analyses, with the promise of faster and earlier diagnosis targeted for particular individuals. As Brahmachari acknowledged, T2B is a heterogeneous and multifactorial disease (as is COPD). Pathogens in the gut moreover are less like individual causes than balances of bacterial ecologies whose therapies might involve rebalancing rather than trying to eliminate a bacterium or class of bacteria. BGI sequenced the intestinal bacteria of 345 people in China, of whom 175 are diabetics to seek out differences that make a difference.
Similar work is being done in Denmark and across Europe. A second step in confirming findings is to grow bacteria from mice with diabetes to see which or what imbalance might cause diabetes. The intestinal microbiome or bacteria (which vastly outnumber the human cells in our bodies) is, as Wang Jun and others put it, our "second genome", and understanding its effects on our bodies, he argues, might well herald the era of personalized medicine, as well as gentler, more holistic therapies "in the not too distant future". "Holistic" here, as Wang Jian's biography makes clear, is one of those semantic switches that can signify an openness to traditional Chinese (and other) medicine (TCM), or on the contrary an insistence on the difficult work of actually tracing out the multiple interconnections that compose our biologies and ecologies.
While the exchange between Brahmachari and Wang is amusing and goodnatured, there is an underlying irritation from BGI leaders who know well that their colleagues have often tried to position them as 'research without scientific questions;' 'no brain only have muscle; do the dirty work'; 'we [in the West] do science, you do the dirty work, just sequencing.' These phrases can be self-serving and ethnocentric, but the self-servingness is also an active tactic of marginalizing.
BGI leaders cite these phrases now both as badge of honor (of systematically overcoming obstacles and working up the scientific as well as commercial value chain) and as lingering irritation at the continued struggle for recognition (which today they are finally achieving, and in the process bringing to Philadelphia and The northern and southern centers of CAS then claimed some credit, and Jiang said they could have credit, but after ten years no body remembers them, the National Genome Center, North and South. They are gone, like lots of U.S. genome centers, erased from memory. The human genome map was declared finished in 2003. It was sort of complete, it's never complete, they just call it the final map. The point, to use Ulrich Beck's useful term, is that methodological nationalism (seeing everything through nation-state categories) can be misleading.
Davis models of integrative collaboration). BGI has branches and offices now in
The republic of science --while hardly denying or ignoring national boundaries, intellectual property and other legal terrains and ethical review processes -also maps across those political boundaries. It works through qualitatively structured networks, including mentorship and friendship lineages. Collaboration is as much about building these as about project outcomes and temporalities.
Conclusions
If there is utility in the kind of juxtaposition attempted in this essay, it is one of critically reevaluating history of ideas, institution-centric, nation-centric, or fieldcentric accounts of science in a globalized terrain. Much is to be gained by analysis of statistical flows of international students and postdocs, but much is also to be gained by a more fine grained analysis of actual networks, working collaborations, and exchange of ideas. If one stereotypically understands Singapore as having (6) The 10 year $100 million accelerated research initiative to study 1,000 retired National Football League players, funded by the NFL players' union, awarded to Harvard University (announced in January 2013). Over 100 concussion-related lawsuits have been filed against the league, with thousands of players claiming the NFL did not do enough to inform them of the long-term dangers from repeat brain injuries and protect them. Attention has focused on chronic traumatic encephalopathy, an Alzheimer's like condition (focusing on the tau protein lodged in the amygdyla and hypocampus), and the potential of LED (light emitting diodes) for preventing permanent brain damage from concussions, suicides, erratic behavior and depression. The study will also attend to searing joint pain and heart problems linked to extreme strength training, and dramatically shorted life spans. 34 vi The anthropological demand for ethnographic specificity seeks to follow out the networks in particular fields and across events in order to understand structural changes at a finer granularity than just aggregate manpower figures. More than half a million Chinese students have been trained in the U.S., U.K Japan, France, Germany, Australia and Denmark, and a large number have returned to China (Wang Hongyi 2013) . While many have noted numerical flows of this sort, it remains unclear where and how these returnees have been able to contribute, and there remains a good deal of concern that the best remain abroad, and that the talents of those who return are not always used in the best ways, or that the most accomplished and experienced in the actual practicalities of scientific management at best come part time keeping their jobs abroad should political winds shift. In this respect too, BGI provides a rather unique case of being able to both do domestic training and negotiate, government, NGO, and private corporate structures while also collaborating internationally. Indeed Wang Jun has reversed the relationship deployed by many diaspora Chinese by being Professor in Copenhagen while largely working from Shenzhen. xi After working on a 1% region of the Human Genome, the next step was to try doing the rice genome, particularly the indica hybrid variety used in China and Southeast Asia. An International Consortium was working on japonica, and Syngenta and Monsanto also had rice genome projects, again a struggle between 36 private and public efforts and modes of innovative competition. Yang Huanming is pleased that BGI's work on the rice genome was immediately put into the public domain. The rice genome proved to be more and more interesting. Although the smallest genome by far of the cereals, it was an order of magnitude larger than the region of the human genome that BGI had cut its teeth on. Although seen as a model organism for monocots, it had quite unusual features that set it apart. And by working on a hybrid, thus having to start with two parental strains, BGI set the ground work for larger comparative genomics analyses of rice strains and for future breeding and engineering of new strains. 
